The Food and Drug Administration yesterday announced safety labeling changes for fluoroquinolone antibiotics to strengthen warnings about the risk of mental health side effects and serious blood sugar disturbances. Based on a recent FDA review of adverse event reports and the medical literature, the updated labeling will highlight mental health side effects including disturbances in attention, disorientation, agitation, nervousness, memory impairment and delirium, and the potential risk of coma with hypoglycemia. Fluoroquinolone antibiotics are used to treat certain serious bacterial infections.
 

Related News Articles

Headline
About 80 percent of new HIV infections in the U.S. in 2016 were transmitted from the nearly 40 percent of people with HIV who either did not know they had HIV…
Headline
Historic flooding in parts of the Midwest caused a number of Nebraska hospitals to be inaccessible by ground transportation, the Nebraska Hospital Association…
Headline
The Senate Appropriations Committee’s Subcommittee on Labor, Health and Human Services, Education and Related Agencies today held a
Insights and Analysis
In this AHA Stat Blog, Institute for Diversity and Health Equity President and CEO Duane Reynolds shares some takeaways from the recent ACHE conference and…
Insights and Analysis
This week, as part of the South by Southwest (SXSW) festival’s Interactive Health and MedTech track, the American Hospital Association and hospital leaders…
Headline
A federal court has ordered a Texas-based company to stop producing compounded drug products intended to be sterile until the company complies with the Federal…